Schering anesthesia med makes Euro-debut

Schering-Plough has launched its anesthesia-reversal drug Bridion in Sweden, with plans to inaugurate the drug in the U.K. and Germany soon. Known generically as sugammadex, the drug was rejected for U.S. sale by the FDA in August, on concerns about allergic reactions. The agency said it may ask for more data on those reactions. Report

Suggested Articles

It’s final: England won’t be covering AZ’s quick-selling Tagrisso in previously untreated non-small cell lung cancer patients with EGFR mutatations.

Top J&J meds have managed to hang onto market share in the face of new generics and biosims, but the drugmaker expects the pain to continue in 2020.

Lonza’s search for a new CEO is expected to be wrapped up this year as the CDMO homes in on a list of veterans from outside the company.